Literature DB >> 3968312

Magnesium deficiency and myocardial infarct size in the dog.

C Chang, P J Varghese, J Downey, S Bloom.   

Abstract

Although epidemiologic data suggest a relation between myocardial infarction death rates and dietary intake of magnesium, there are no experimental studies reflecting such a phenomenon. It is now reported that beagle dogs kept on a severely magnesium-deficient diet for 100 days develop a larger infarct than do control animals. Control animals were either kept on the same diet as experimental animals with supplementary magnesium, or were fed standard dog chow. The control groups were indistinguishable and were therefore pooled. Infarction was produced by occlusion of the left anterior descending coronary artery for 1 hour followed by 4 hours of reperfusion. Slices of ventricular myocardium, 5 mm thick, were made from the apex to the base. Ischemic muscle, considered to be the muscle at risk, was delineated by a microsphere-autoradiographic method, and necrotic muscle was delineated by tetrazolium stain. Involved areas were measured by planimetry, and these integrated to produce the volume. The volumes of muscle made ischemic were similar in the experimental and control groups. The volumes of necrotic muscle, however, were less in the control than in the experimental animals. The ratio of necrotic muscle volume to the volume of muscle at risk was greater in the experimental animals than in the control animals by a factor of almost two (p less than 0.004). These experiments indicate that, under the conditions used here, animals fed a magnesium-deficient diet develop a larger infarct than do control animals. This could occur either through decreased postocclusion collateral flow or increased vulnerability of the ischemic muscle in magnesium-deficient animals. Although these experiments cannot rule out an effect on postocclusion collateral flow, they do suggest that electrolyte abnormalities related to magnesium deficiency are of such a character as to increase myocardial vulnerability to injury.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3968312     DOI: 10.1016/s0735-1097(85)80048-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  8 in total

Review 1.  Magnesium in acute myocardial infarction: scientific, statistical, and economic rationale for its use.

Authors:  E M Antman; M S Seelig; K Fleischmann; J Lau; K Kuntz; C S Berkey; M W McIntosh
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

Review 2.  Neurogenic inflammation and cardiac dysfunction due to hypomagnesemia.

Authors:  Jay H Kramer; Christopher Spurney; Micaela Iantorno; Constantine Tziros; I-Tong Mak; M Isabel Tejero-Taldo; Joanna J Chmielinska; Andrei M Komarov; William B Weglicki
Journal:  Am J Med Sci       Date:  2009-07       Impact factor: 2.378

Review 3.  Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence.

Authors:  Koon K Teo; Salim Yusuf
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Morphologic features and nuclide composition of infarction-associated cardiac myocyte mineralization in humans.

Authors:  V G Lockard; S Bloom
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

5.  Effects of magnesium, ouabain and bumetanide on 86rubidium uptake in a human atrial cell line.

Authors:  P C Borchgrevink; M P Ryan
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 6.  Magnesium, myocardial ischaemia and arrhythmias. The role of magnesium in myocardial infarction.

Authors:  A Dubey; R Solomon
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

7.  Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials.

Authors:  K K Teo; S Yusuf; R Collins; P H Held; R Peto
Journal:  BMJ       Date:  1991-12-14

8.  Severe electrolyte disorders following cardiac surgery: a prospective controlled observational study.

Authors:  Kees H Polderman; Armand R J Girbes
Journal:  Crit Care       Date:  2004-10-22       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.